CMLUN24013 // EA5221 // Baumgart
Basic Study Information
Purpose:
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab)
versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy
with monoclonal antibodies, such as pembrolizumab, may help the body's immune system
attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Chemotherapy drugs work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Megan Baumgart
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search